NASDAQ · CPIX
Cumberland Pharmaceuticals Inc.
$4.69+$0.34 (+7.82%)
Cumberland Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.46% below the high.
Loading market information…
NASDAQ · RMTI · USD
Stock price, earnings
Quote as of Oct 30, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Rockwell Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.19% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Rockwell Medical, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Rockwell Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:51 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | -$0.40-33.33% vs estimate | $18.91M+8.33% vs estimate |
|---|
| Q4 2024 | Mar 20, 2025 | -$0.20-200.0% vs estimate | $24.67M+4.95% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | $0.50+400.0% vs estimate | $28.31M+6.82% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $20.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.69+$0.34 (+7.82%)
Cumberland Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.46% below the high.
$1.03-$0.04 (-3.74%)
Talphera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.39% below the high.
$2.16-$0.07 (-3.29%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 63.33% below the high.
$9.80-$0.01 (-0.1%)
Star Equity Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 17.72% below the high.
$2.04$0.00 (0.0%)
Mural Oncology plc’s quoted price sits in the lower half of its reported 52-week range, 56.96% below the high.
$2.93-$0.15 (-4.87%)
Evaxion Biotech A/S’s quoted price sits in the lower half of its reported 52-week range, 57.66% below the high.
$2.38-$0.06 (-2.46%)
Quantum BioPharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 80.9% below the high.
$0.93-$0.04 (-4.39%)
NeuroOne Medical Technologies Corporation’s quoted price sits in the lower half of its reported 52-week range, 84.85% below the high.
